Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims.
Gregory Yoke Hong LipVirginia NoxonAmiee KangXuemei LuoNipun AtrejaStella HanDong ChengJenny JiangLisa AbramovitzSteven DeitelzweigPublished in: Journal of thrombosis and thrombolysis (2024)
The final population consisted of 2,611 apixaban-dabigatran, 12,165 apixaban-rivaroxaban, and 2,672 dabigatran-rivaroxaban pairs. Apixaban vs. dabigatran was associated with a lower risk of stroke/SE (hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.39-0.96) and MB (HR: 0.67; 95% CI: 0.50-0.91). Apixaban vs. rivaroxaban was associated with a similar risk of stroke/SE (HR: 0.88; 95% CI: 0.73-1.07) and a lower risk of MB (HR: 0.60; 95% CI: 0.52-0.68). There was no significant difference in either risk between dabigatran and rivaroxaban. These results provide important insights into how the risks of stroke/SE and MB for NVAF patients vary when switching from warfarin to different DOACs.
Keyphrases
- atrial fibrillation
- direct oral anticoagulants
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- heart failure
- end stage renal disease
- venous thromboembolism
- healthcare
- newly diagnosed
- percutaneous coronary intervention
- chronic kidney disease
- peritoneal dialysis
- risk assessment
- blood brain barrier
- patient reported outcomes
- mitral valve
- human health
- acute coronary syndrome
- affordable care act